STUDY OF THE IN VITRO EFFECT OF THE NONPEPTIDE THROMBOPOIETIN -RECEPTOR AGONIST SB-497115 (ELTROMBOPAG) ON MEGAKARYOPOIESIS OF PATIENTS WITH LOW/INTERMEDIATE-I RISK MYELODYSPLASTIC SYNDROME

被引：0
|
作者：
Mavroudi, I. [1 ]
Psyllaki, M. [1 ]
Pyrovolaki, K. [1 ]
Gvazava, G. [1 ]
Kalpadakis, C. [1 ]
Papadaki, H. A. [1 ]
机构：
[1] Univ Crete, Sch Med, Iraklion, Greece
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0232
引用
收藏
页码：91 / 92
页数：2
相关论文
共 12 条
  • [1] The in vitro effect of SB-497115 (Eltrombopag) on megakaryopoiesis of patients with low/intermediate-1 IPSS myelodysplastic syndrome
    Papadaki, H.
    Mavroudi, I.
    Psyllaki, M.
    Pyrovolaki, K.
    Papadaki, V.
    Kalpadakis, C.
    Mastrodimou, S.
    Kaparou, M.
    Kanellou, P.
    Gvazava, G.
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S47 - S48
  • [2] Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist
    Erickson-Miller, Connie L.
    Delorme, Evelyne
    Tian, Shin-Shay
    Hopson, Christopher B.
    Landis, Amy J.
    Valoret, Elizabeth I.
    Sellers, Teresa S.
    Rosen, Jon
    Miller, Stephen G.
    Luengo, Juan I.
    Duffy, Kevin J.
    Jenkins, Julian M.
    [J]. STEM CELLS, 2009, 27 (02) : 424 - 430
  • [3] Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome
    Mavroudi, Irene
    Pyrovolaki, Katerina
    Pavlaki, Konstantia
    Kozana, Androniki
    Psyllaki, Maria
    Kalpadakis, Christina
    Pontikoglou, Charalampos
    Papadaki, Helen A.
    [J]. LEUKEMIA RESEARCH, 2011, 35 (03) : 323 - 328
  • [4] Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome
    Will, Britta
    Kawahara, Masahiro
    Luciano, Julia P.
    Bruns, Ingmar
    Parekh, Samir
    Erickson-Miller, Connie L.
    Aivado, Manuel A.
    Verma, Amit
    Steidl, Ulrich
    [J]. BLOOD, 2009, 114 (18) : 3899 - 3908
  • [5] The non-peptide thrombopoietin receptor agonist Eltrombopag (SB-497115, Promacta/Revolade) does not stimulate malignant growth of bone marrow cells from patients with acute myeloid leukemia or myelodysplastic syndromes
    Will, B.
    Luciano, J.
    Kawahara, M.
    Erickson-Miller, C.
    Verma, A.
    Aivado, M.
    Steidl, U.
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S46 - S47
  • [6] A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine
    Svensson, Tobias
    Chowdhury, Onima
    Garelius, Hege
    Lorenz, Fryderyk
    Saft, Leonie
    Jacobsen, Sten-Eirik
    Hellstrom-Lindberg, Eva
    Cherif, Honar
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (05) : 439 - 445
  • [7] A PILOT PHASE ONE DOSE FINDING SAFETY STUDY OF A THROMBOPOIETIN-RECEPTOR AGONIST, ELTROMBOPAG, IN PATIENTS WITH MYELODYSPLASTIC SYNDROME TREATED WITH AZACITIDINE
    Svensson, T.
    Garelius, H.
    Lorenz, F.
    Saft, L.
    Hellstrom-Lindberg, E.
    Cherif, H.
    [J]. HAEMATOLOGICA, 2013, 98 : 251 - 251
  • [8] Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Results of a Randomized, Double-Blind, Placebo(PBO)-Controlled Study
    Giagounidis, Aristoteles
    Mufti, Ghulam J.
    Kantarjian, Hagop M.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Szer, Jeffrey
    Kuendgen, Andrea
    Platzbecker, Uwe
    Gaidano, Gianluca
    Jedrzejczak, Wieslaw
    Hu, Kuolung
    Yang, Allen S.
    Jun, Susie
    [J]. BLOOD, 2011, 118 (21) : 57 - 58
  • [9] Treatment With Romiplostim, a Thrombopoietin-Receptor Agonist, In Thrombocytopenic Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndrome: Updated Follow-Up Results For Acute Myeloid Leukemia and Survival From a Randomized, Double-Blind, Placebo-Controlled Study
    Kantarjian, Hagop M.
    Mufti, Ghulam J.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Szer, Jeffrey
    Platzbecker, Uwe
    Kuendgen, Andrea
    Gaidano, Gianluca
    Wiktor-Jedrzejczak, Wieslaw
    Meibohm, Anne
    Lopez, Angela
    Giagounidis, Aristoteles
    [J]. BLOOD, 2013, 122 (21)
  • [10] Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation
    Abaza, Yasmin
    Hidalgo-Lopez, Juliana E.
    Verstovsek, Srdan
    Jabbour, Elias
    Ravandi, Farhad
    Borthakur, Gautam
    Estrov, Zeev
    Alvarado, Yesid
    Burger, Jan
    Schneider, Heather
    Soltysiak, Kelly A.
    Wei, Yue
    Kantarjian, Hagop M.
    Bueso-Ramos, Carlos E.
    Garcia-Manero, Guillermo
    [J]. LEUKEMIA RESEARCH, 2018, 73 : 78 - 85
12